{
  "main_header": {
    "sid": 1002834,
    "name": "Lasa Supergeneri",
    "stock_name": "Lasa Supergeneri",
    "full_name": "Lasa Supergenerics Ltd",
    "name_url": "stocks-analysis/lasa-supergeneri",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "6.25",
    "chg": 0.29,
    "chgp": "4.87%",
    "dir": 1,
    "prev_price": "5.96",
    "mcapval": "31.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540702,
    "symbol": "LASA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE670X01014",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "17.39 k",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/lasa-supergeneri-1002834-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 201,
    "sid": "1002834",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/lasa-supergenerics-1002834"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Mar-2026",
      "details": "Closure of trading window for the quarter and year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended 31St December 2025",
      "datetime": "13-Feb-2026",
      "details": "Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations 2015 we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.00 P.M. and concluded at 03.15 P.M. inter- alia have considered and approved the following: 1. The Unaudited Financial Results of the Company for the quarter ended December 31 2025. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Results For Quarter Ended 31St December 2025",
      "datetime": "13-Feb-2026",
      "details": "Results for quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Lasa Supergenerics Ltd has declared <strong>2%</strong> dividend, ex-date: 16 Sep 22",
          "dt": "2022-09-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News